The rationale to test the efficacy of checkpoint inhibitors in OC arises from the observation that intratumoral T-cells directly correlate with clinical outcome [10] and that the PD-1/PD-L1 pathway may play a relevant role in the immune evasion of malignant ovarian tumors [11]. The gene discussed is PDCD1; the disease is ovarian cancer.